In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole.
The in vitro antifungal activity of albendazole, a benzimidazole widely used as an antihelmintic drug in humans, was investigated and assessed for its activity against Aspergillus spp. Forty-eight isolates, representing the most frequent species found in human pathology [Aspergillus fumigatus (n = 27), Aspergillus flavus (n = 10), Aspergillus terreus (n = 7), Aspergillus nidulans (n = 3) and Aspergillus niger (n = 1)], and one quality control strain (A. niger ATCC 9804 83435) were tested according to the NCCLS M38-P methodology for moulds. All the strains were susceptible to albendazole, with homogeneous MICs for each species; three strains were resistant to itraconazole.
Berthet
N
N
Laboratoire Interactions Cellulaires Parasite-Hôte ICPH, Faculté de Médecine et Pharmacie, Université Joseph Fourier, F-38706 La Tronche, France.
Faure
O
O
Bakri
A
A
Ambroise-Thomas
P
P
Grillot
R
R
Brugère
J-F
JF
D015766:Albendazole / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification*; D025141:Drug Resistance, Fungal / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods
D000935:Antifungal Agents; D015766:Albendazole